Cargando…

Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course

BACKGROUND: We reported previously that (18)F-2-fluoro-2-deoxyglucose positron emission tomography/ computed tomography (FDG PET/CT) had potential for evaluating early response to treatment by tyrosine kinase inhibitors (TKIs) in advanced renal cell carcinoma (RCC). This time we investigated the rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueno, Daiki, Yao, Masahiro, Tateishi, Ukihide, Minamimoto, Ryogo, Makiyama, Kazuhide, Hayashi, Narihiko, Sano, Futoshi, Murakami, Takayuki, Kishida, Takeshi, Miura, Takeshi, Kobayashi, Kazuki, Noguchi, Sumio, Ikeda, Ichiro, Ohgo, Yoshiharu, Inoue, Tomio, Kubota, Yoshinobu, Nakaigawa, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418566/
https://www.ncbi.nlm.nih.gov/pubmed/22551397
http://dx.doi.org/10.1186/1471-2407-12-162
_version_ 1782240649292021760
author Ueno, Daiki
Yao, Masahiro
Tateishi, Ukihide
Minamimoto, Ryogo
Makiyama, Kazuhide
Hayashi, Narihiko
Sano, Futoshi
Murakami, Takayuki
Kishida, Takeshi
Miura, Takeshi
Kobayashi, Kazuki
Noguchi, Sumio
Ikeda, Ichiro
Ohgo, Yoshiharu
Inoue, Tomio
Kubota, Yoshinobu
Nakaigawa, Noboru
author_facet Ueno, Daiki
Yao, Masahiro
Tateishi, Ukihide
Minamimoto, Ryogo
Makiyama, Kazuhide
Hayashi, Narihiko
Sano, Futoshi
Murakami, Takayuki
Kishida, Takeshi
Miura, Takeshi
Kobayashi, Kazuki
Noguchi, Sumio
Ikeda, Ichiro
Ohgo, Yoshiharu
Inoue, Tomio
Kubota, Yoshinobu
Nakaigawa, Noboru
author_sort Ueno, Daiki
collection PubMed
description BACKGROUND: We reported previously that (18)F-2-fluoro-2-deoxyglucose positron emission tomography/ computed tomography (FDG PET/CT) had potential for evaluating early response to treatment by tyrosine kinase inhibitors (TKIs) in advanced renal cell carcinoma (RCC). This time we investigated the relation of the early assessment by FDG PET/CT to long-term prognosis with an expanded number of patients and period of observation. METHODS: Patients for whom TKI treatment for advanced RCC was planned were enrolled. FDG PET/CT was performed before TKI treatment and after one month of TKI treatment. The relations of the FDGPET/CT assessment to progression free survival (PFS) and overall survival (OS) were investigated. RESULTS: Thirty-five patients were enrolled (sunitinib 19 cases, sorafenib 16 cases). The patients with RCC showing high SUVmax in pretreatment FDG PET/CT demonstrated short PFS (P =0.024, hazard ratio 1.137, 95% CI 1.017-1.271) and short OS (P =0.004, hazard ratio 1.210 95% CI 1.062-1.379). Thirty patients (sunitinib 16 cases, sorafenib 14 cases) were evaluated again after 1 month. The PFS of the patients whose SUVmax decreased<20% was shorter than that of the patients whose SUVmax decreased<20% (P = 0.027, hazard ratio 3.043, 95% CI 1.134-8.167). The PFS of patients whose tumor diameter sum increased was shorter than that of the patient with tumors whose diameter sum did not (P =0.006, hazard ratio 4.555, 95% CI 1.543-13.448). The patients were classified into three response groups: good responder (diameter sum did not increase, and SUVmax decreased ≥ 20%), intermediate responder (diameter sum did not increase, and SUVmax decreased<20%), and poor responder (diameter sum increased, or one or more new lesions appeared). The median PFS of good, intermediate, and poor responders were 458 ± 146 days, 131 ± 9 days, and 88 ± 26 days (good vs. intermediate P = 0.0366, intermediate vs. poor P = 0.0097, log-rank test). Additionally the mean OSs were 999 ± 70 days, 469 ± 34 days, and 374 ± 125 days, respectively (good vs. intermediate P = 0.0385, intermediate vs. poor P = 0.0305, log-rank test). CONCLUSIONS: The evaluation of RCC response to TKI by tumor size and FDG uptake using FDG PET/CT after 1 month can predict PFS and OS.
format Online
Article
Text
id pubmed-3418566
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34185662012-08-15 Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course Ueno, Daiki Yao, Masahiro Tateishi, Ukihide Minamimoto, Ryogo Makiyama, Kazuhide Hayashi, Narihiko Sano, Futoshi Murakami, Takayuki Kishida, Takeshi Miura, Takeshi Kobayashi, Kazuki Noguchi, Sumio Ikeda, Ichiro Ohgo, Yoshiharu Inoue, Tomio Kubota, Yoshinobu Nakaigawa, Noboru BMC Cancer Research Article BACKGROUND: We reported previously that (18)F-2-fluoro-2-deoxyglucose positron emission tomography/ computed tomography (FDG PET/CT) had potential for evaluating early response to treatment by tyrosine kinase inhibitors (TKIs) in advanced renal cell carcinoma (RCC). This time we investigated the relation of the early assessment by FDG PET/CT to long-term prognosis with an expanded number of patients and period of observation. METHODS: Patients for whom TKI treatment for advanced RCC was planned were enrolled. FDG PET/CT was performed before TKI treatment and after one month of TKI treatment. The relations of the FDGPET/CT assessment to progression free survival (PFS) and overall survival (OS) were investigated. RESULTS: Thirty-five patients were enrolled (sunitinib 19 cases, sorafenib 16 cases). The patients with RCC showing high SUVmax in pretreatment FDG PET/CT demonstrated short PFS (P =0.024, hazard ratio 1.137, 95% CI 1.017-1.271) and short OS (P =0.004, hazard ratio 1.210 95% CI 1.062-1.379). Thirty patients (sunitinib 16 cases, sorafenib 14 cases) were evaluated again after 1 month. The PFS of the patients whose SUVmax decreased<20% was shorter than that of the patients whose SUVmax decreased<20% (P = 0.027, hazard ratio 3.043, 95% CI 1.134-8.167). The PFS of patients whose tumor diameter sum increased was shorter than that of the patient with tumors whose diameter sum did not (P =0.006, hazard ratio 4.555, 95% CI 1.543-13.448). The patients were classified into three response groups: good responder (diameter sum did not increase, and SUVmax decreased ≥ 20%), intermediate responder (diameter sum did not increase, and SUVmax decreased<20%), and poor responder (diameter sum increased, or one or more new lesions appeared). The median PFS of good, intermediate, and poor responders were 458 ± 146 days, 131 ± 9 days, and 88 ± 26 days (good vs. intermediate P = 0.0366, intermediate vs. poor P = 0.0097, log-rank test). Additionally the mean OSs were 999 ± 70 days, 469 ± 34 days, and 374 ± 125 days, respectively (good vs. intermediate P = 0.0385, intermediate vs. poor P = 0.0305, log-rank test). CONCLUSIONS: The evaluation of RCC response to TKI by tumor size and FDG uptake using FDG PET/CT after 1 month can predict PFS and OS. BioMed Central 2012-05-02 /pmc/articles/PMC3418566/ /pubmed/22551397 http://dx.doi.org/10.1186/1471-2407-12-162 Text en Copyright ©2012 Ueno et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ueno, Daiki
Yao, Masahiro
Tateishi, Ukihide
Minamimoto, Ryogo
Makiyama, Kazuhide
Hayashi, Narihiko
Sano, Futoshi
Murakami, Takayuki
Kishida, Takeshi
Miura, Takeshi
Kobayashi, Kazuki
Noguchi, Sumio
Ikeda, Ichiro
Ohgo, Yoshiharu
Inoue, Tomio
Kubota, Yoshinobu
Nakaigawa, Noboru
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
title Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
title_full Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
title_fullStr Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
title_full_unstemmed Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
title_short Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
title_sort early assessment by fdg-pet/ct of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418566/
https://www.ncbi.nlm.nih.gov/pubmed/22551397
http://dx.doi.org/10.1186/1471-2407-12-162
work_keys_str_mv AT uenodaiki earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT yaomasahiro earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT tateishiukihide earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT minamimotoryogo earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT makiyamakazuhide earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT hayashinarihiko earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT sanofutoshi earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT murakamitakayuki earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT kishidatakeshi earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT miuratakeshi earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT kobayashikazuki earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT noguchisumio earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT ikedaichiro earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT ohgoyoshiharu earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT inouetomio earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT kubotayoshinobu earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse
AT nakaigawanoboru earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse